Faecal Microbiota Transplantation for Liver Cirrhosis
Faecal Microbiota Transplantation to Prevent Complications, Progression and Mortality of Liver Cirrhosis
University of Aarhus
220 participants
Jul 1, 2021
INTERVENTIONAL
Conditions
Summary
The purpose is to investigate the effect of faecal microbiota transplantation (FMT) on complications, progression, and mortality of patients with liver cirrhosis. Further, the investigators want to examine the impact of FMT on the gut microbiota, gut barrier function, systemic inflammation, and immune function.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
All participant will receive three applications of either FMT or placebo and afterwards followed for 1 year.
Placebo
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04932577